Aachen, Germany & Victoria, Australia (OTE) – Grünenthal, a global
leader in pain management and related diseases,
and Clinect Pty Ltd („Clinect“), an Australian based company focussed
on supporting access to unique products, announced today that they
have entered into a definitive agreement whereby Clinect will have
the exclusive Australian rights to Qutenza®, a topical, non-systemic,
non-opioid patch indicated for the management of peripheral
neuropathic pain. Under the agreement, Clinect will be responsible
for obtaining marketing authorisation for Qutenza® in Australia and,
upon approval, marketing and distributing the product in Australia.
„We firmly believe in the benefits that this non-opioid treatment
option can provide to people suffering from peripheral neuropathic
pain and continue to work on expanding its footprint to reach more
patients worldwide,“ says Jan Adams, Chief Commercial Officer (CCO)
at Grünenthal. „Clinect is an experienced specialist with a strong
presence in Australia, and I look forward to joining forces with
their team to bring our brand to Australia, a major market of the
Asia-Pacific region.“
„We value the opportunity to work alongside Grünenthal, a global
leader in pain management, to introduce Qutenza® to the Australian
market,” said Merryn Wallace, General Manager at Clinect. “This
agreement reflects our shared commitment to improving patient
outcomes and aligns with Clinect’s strategy of partnering with
companies who bring truly differentiated therapies to our region.“
Grünenthal acquired the global rights to Qutenza® in 2018 as part
of its M&A-driven growth strategy. Since 2017, the company has
invested more than Ꞓ2.3 billion in successful M&A transactions,
diversifying its portfolio, enhancing its profitability, and driving
business growth. Grünenthal continues to expand the footprint of the
acquired brands and to create synergies throughout Grünenthal’s
infrastructure, including manufacturing, supply, logistics, and
commercial activities.
About Qutenza®
In Europe, Qutenzais indicated for the treatment of peripheral
neuropathic pain in adults, either alone or in combination with other
medicinal products for the treatment of pain. For further
information, please visit www.grunenthalhealth.com .
Qutenza (capsaicin) 8% topical system is approved in the US for
the treatment of neuropathic pain associated with postherpetic
neuralgia and for the treatment of neuropathic pain associated with
diabetic peripheral neuropathy (DPN) of the feet in adults. Important
US safety information is available at www.qutenza.com .
About Grünenthal
Grünenthal is a global leader in pain management and related
diseases. As a science-based, fully integrated pharmaceutical
company, we have a long track record of bringing innovative
treatments and state-of-the-art technologies to patients worldwide.
Our purpose is to change lives for the better – and innovation is our
passion. We focus all our activities and efforts on working towards
our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has
affiliates in 28 countries across Europe, Latin America, and the U.S.
Our products are available in approx. 100 countries. In 2024,
Grünenthal employed around 4,300 people and achieved revenues of Ꞓ1.8
billion. More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group | Instagram: grunenthal
About Clinect
Clinect is part of the EBOS Group (NZX/ASX Code: EBO) the largest
and most diversified Australasian marketer, wholesaler and
distributor of healthcare, medical and pharmaceutical products.
Clinect supports patients in Australia and New Zealand with
established and innovative products via strategic partnering
relationships. Clinect together with its affiliates, will market and
distribute the product in Australia.
Digital press kit: http://www.ots.at/pressemappe/DE118252/aom